Completed Access to Information Requests

Follow:

  • RSS
  • Cite

    Cite

    APA

    Open Government - Government of Canada. (2017, December 10). Completed Access to Information Requests. Retrieved from http://open.canada.ca/en/search/ati?f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&amp%3Bamp%3Bf%5B1%5D=ss_ati_organization_en%3AAgriculture%20and%20Agri-Food%20Canada&amp%3Bamp%3Bf%5B2%5D=ss_ati_organization_en%3ASocial%20Sciences%20and%20Humanities%20Research%20Council%20of%20Canada&amp%3Bamp%3Bati%5B0%5D=ss_ati_organization_en%3ANational%20Film%20Board&amp%3Bamp%3Bati%5B1%5D=ss_ati_organization_en%3AThe%20Correctional%20Investigator%20Canada&amp%3Bati%5B0%5D=ss_ati_organization_en%3AOffice%20of%20the%20Commissioner%20of%20Lobbying%20of%20Canada&ati%5B0%5D=%3AGlobal%20Affairs%20Canada&ati%5B1%5D=%3ANational%20Research%20Council%20Canada&ati%5B2%5D=%3AOffice%20of%20the%20Information%20Commissioner%20of%20Canada&ati%5B3%5D=%3APublic%20Safety%20Canada&ati%5B4%5D=ati_month_en%3AMarch&ati%5B5%5D=ati_organization_en%3AHealth%20Canada&ati%5B6%5D=ati_organization_en%3ANational%20Defence&ati%5B7%5D=ati_organization_en%3ANational%20Film%20Board&ati%5B8%5D=ati_organization_en%3AWestern%20Economic%20Diversification%20Canada&search_api_fulltext=&sort_by=year&sort_order=DESC&f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&page=5
    MLA

    “Completed Access to Information Requests.” Open Government - Government of Canada, 10 December 2017, http://open.canada.ca/en/search/ati?f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&amp%3Bamp%3Bf%5B1%5D=ss_ati_organization_en%3AAgriculture%20and%20Agri-Food%20Canada&amp%3Bamp%3Bf%5B2%5D=ss_ati_organization_en%3ASocial%20Sciences%20and%20Humanities%20Research%20Council%20of%20Canada&amp%3Bamp%3Bati%5B0%5D=ss_ati_organization_en%3ANational%20Film%20Board&amp%3Bamp%3Bati%5B1%5D=ss_ati_organization_en%3AThe%20Correctional%20Investigator%20Canada&amp%3Bati%5B0%5D=ss_ati_organization_en%3AOffice%20of%20the%20Commissioner%20of%20Lobbying%20of%20Canada&ati%5B0%5D=%3AGlobal%20Affairs%20Canada&ati%5B1%5D=%3ANational%20Research%20Council%20Canada&ati%5B2%5D=%3AOffice%20of%20the%20Information%20Commissioner%20of%20Canada&ati%5B3%5D=%3APublic%20Safety%20Canada&ati%5B4%5D=ati_month_en%3AMarch&ati%5B5%5D=ati_organization_en%3AHealth%20Canada&ati%5B6%5D=ati_organization_en%3ANational%20Defence&ati%5B7%5D=ati_organization_en%3ANational%20Film%20Board&ati%5B8%5D=ati_organization_en%3AWestern%20Economic%20Diversification%20Canada&search_api_fulltext=&sort_by=year&sort_order=DESC&f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&page=5
    (Report an issue with citation)
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 869 record(s)

Req # A-2021-001161

Adverse Drug Reactions (ADRs) for FUROSEMIDE. Report numbers: E2B_04009172, 000931911, E2B_03904593, 000935299, 000928248, E2B_03541719, E2B_03557949, 000929346, 000929885, E2B_03542646, E2B_03636662, E2B_03773673, E2B_03799830.

Organization: Health Canada

380 page(s)
March 2023

Req # A-2021-001183

Adverse Drug Reactions (ADRs). Report numbers: 426234, 606501, 908164, 908363, 908470, 916212, 917022, 917291, 920947, 920997, 921099, 921852, 923481, 927077, 927170, 928706, E2B_02727599, 929796, 931867, 933049.

Organization: Health Canada

323 page(s)
March 2023

Req # A-2021-001651

Adverse Drug Reactions (ADRs). Report numbers: 000964188, 000966616.

Organization: Health Canada

12 page(s)
March 2023

Req # A-2022-000039

Adverse Drug Reaction (ADR). Report number: E2B_04777994.

Organization: Health Canada

13 page(s)
March 2023

Req # A-2022-000114

Adverse Drug Reactions (ADRs). Report numbers: E2B_04996532, E2B_05023248, E2B_05009592, E2B_05016195, E2B_05042650, E2B_05003855, E2B_05009626, E2B_05041696, 000981805, E2B_05041390.

Organization: Health Canada

212 page(s)
March 2023

Req # A-2022-000310

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-116049-739.

Organization: Health Canada

5 page(s)
March 2023

Req # A-2022-000348

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-120713-906.

Organization: Health Canada

36 page(s)
March 2023

Req # A-2022-000576

Adverse Drug Reactions (ADRs). Report numbers: E2B_02895902, E2B_05128231, E2B_05053764, E2B_04987109, E2B_04966727, E2B_05015795, E2B_04821910, E2B_03587846, E2B_04914551, E2B_04342934.

Organization: Health Canada

340 page(s)
March 2023

Req # A-2022-000626

Adverse Drug Reaction (ADR) for Hydrocortisone acetate/Pramoxine hydrochloride. Report number: 000996794.

Organization: Health Canada

5 page(s)
March 2023

Req # A-2022-000902

Adverse Drug Reactions (ADRs) for Pantoprazole sodium. Report numbers: E2B_05566840, E2B_05589438, E2B_05575121, E2B_05591402, E2B_05552008. ADRs for Mesalazine. Report numbers: E2B_05530426, E2B_05557453, E2B_05596202, E2B_05554526. ADR for Mesalamine. Report number: E2B_05597393.

Organization: Health Canada

1022 page(s)
March 2023
Date modified: